Skip to content
Telehealth Graded
State guide

Wyoming Medicaid and GLP-1s

Wyoming writes short criteria and long follow-ups. Zepbound is approved for sleep apnea in obese adults with a recent sleep study — then reviewed at six months against a five percent weight loss, and again at twelve months against a fresh sleep study. Wegovy needs a BMI of 27 and a named cardiovascular event. Neither is available for weight alone.

Every source on this page was read first-hand in September 2026, and each one below carries the date printed on the document itself.

2
documents cited
6
sourced facts
2
primary sources

What changed, and what the document says

  1. Wegovy needs an event, not a number

    Conditions apply

    Wyoming names the three qualifying histories rather than accepting cardiovascular disease as a category.

    Client must have BMI of 27 or higher with cardiovascular disease defined as prior myocardial infarction, prior stroke, or peripheral artery disease.

    Wyoming MedicaidLast Updated June 8, 2026

  2. Zepbound is a sleep-apnea drug here

    Conditions apply

    The criteria open on the diagnosis, and obesity appears only as a qualifier of who gets approved.

    Client must have diagnosis of moderate to severe obstructive sleep apnea.

    Wyoming MedicaidLast Updated June 8, 2026

  3. Five percent by six months

    Not covered

    The first re-authorization is a weight test, even though the approved indication is a breathing disorder.

    Prior authorization will be required again at 6 months to show at least 5%

    Wyoming MedicaidLast Updated June 8, 2026

  4. A second sleep study at twelve months

    Not covered

    This is the requirement that sets Wyoming apart. Most states stop at a weight threshold; Wyoming asks for the original test again.

    Prior authorization will be required again at 12 months to demonstrate improvement in obstructive sleep apnea as evidenced by another

    Wyoming MedicaidLast Updated June 8, 2026

  5. Metformin before any GLP-1

    Conditions apply

    On the diabetes side Wyoming requires ninety days of metformin in the last year before even a preferred agent, unless cardiovascular disease is present.

    be required before approval can be given for a preferred agent unless ASCVD or risk factors are

    Wyoming MedicaidPreferred Drug List (PDL) June 8, 2026

  6. Where the two drugs sit on the list

    Context

    Neither appears in an obesity class, because Wyoming's list does not have one. Wegovy sits under a liver heading and Zepbound under a sleep one.

    Preferred Drug List (PDL) June 8, 2026

    Wyoming MedicaidPreferred Drug List (PDL) June 8, 2026

Which of these companies serve Wyoming?

Of the 242 companies we grade, 25 publish a list of the states they are licensed in. We checked 214 more and found no such list on any page we read; 3 we have not checked either way.

18 of those lists name Wyoming: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon and Peak Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Sources

Each document below was fetched and read on the date shown beside it, which is the date printed on the document — not always the date in its web address. All of them were read in September 2026, the same session as the rest of this page.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.